Platelet dysfunction is common in individuals with advanced chronic kidney disease, and hemodialysis (HD) may cause further activation of platelets, increasing the risk of bleeding and thrombosis. Thrombocytopenia is a potential complication of HD therapy that offen is multifactorial. Both underlying patient-related or specific HD factors may be responsible. We present a case where the patient developed new-onset thrombocytopenia while undergoing training for home HD using NxStage System One. We present a systematic approach in the evaluation and management of this patient that led us to continue with the completion of home HD training and later discharging him on home therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/1319-2442.352440 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incidence of Thrombocytopenia With Different Continuous Renal Replacement Systems and Modalities in a Cardiac Intensive Care Unit.
J Pharm Pract
November 2024
Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Thrombocytopenia is due to multifactorial causes in critically ill patients. One etiology is continuous renal replacement therapy (CRRT); however, it is unknown if different modalities impact the incidence. To compare the incidence of thrombocytopenia with the NxStage CRRT system using continuous venovenous hemodialysis (CVVHD) compared to the Prismaflex system using continuous venovenous hemodiafiltration (CVVHDF).
View Article and Find Full Text PDFBasiliximab vs. No Induction Therapy in Kidney Transplant Recipients with a Low Immunological Risk Profile Receiving Tacrolimus/Mycophenolate/Steroids Maintenance Immunosuppression.
J Clin Med
October 2024
Division of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Avenue Hippocrate 10, 1200 Brussels, Belgium.
: Induction therapy with basiliximab is recommended in kidney transplant (KT) recipients with a low immunological risk (LIR) profile. Whether basiliximab is associated with a decreased risk of acute rejection (AR) and graft loss is controversial. : In our institution, LIR patients (absence of anti-HLA antibodies before KT) are inducted with basiliximab in case of living-donor KT, while deceased-donor KT recipients receive no induction.
View Article and Find Full Text PDFBridging the Gap Between CKD Management Paradigms in Transplant and Nontransplant Settings: Published Evidence, Challenges, and Perspectives.
Transplantation
August 2024
Department of Nephrology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.
Kidney transplantation (KT) is the best treatment for patients with kidney failure, associated with improved survival and quality of life compared with maintenance dialysis. However, despite constant improvements in the assessment and management of the alloimmune response, KT patients frequently demonstrate a reduced estimated glomerular filtration rate. Therefore, the usual complications of chronic kidney disease (CKD), such as anemia, hypertension, metabolic acidosis, hyperkalemia, or persistent secondary hyperparathyroidism, are highly prevalent after KT.
View Article and Find Full Text PDFCardiovascular Outcomes in Patients on Home Hemodialysis and Peritoneal Dialysis.
Kidney360
February 2024
Division of Nephrology and Hypertension, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio.
Key Points: Home hemodialysis is associated with decreased risk of stroke and acute coronary syndrome relative to peritoneal dialysis. Home hemodialysis is associated with decreased risk of cardiovascular death and all-cause death relative to peritoneal dialysis.
Background: Cardiovascular disease is the leading cause of morbidity and mortality in patients with ESKD.
Closure of Dialysis Clinics in the United States in 2021-2023.
Clin J Am Soc Nephrol
June 2024
The National Forum of ESRD Networks, Henrico, Virginia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!